Prenetics Initiates 2027 IM8 Revenue Guidance at $400M+
PRE has more than doubled off its 52-week low of $7.175.
Summary
Prenetics has initiated 2027 revenue guidance for its IM8 brand at $400 million or more. This is the first time the company has provided a specific revenue target for 2027, following a $1 billion non-dilutive financing facility from General Catalyst and strong IM8 growth. The company also reported second-quarter IM8 revenue of $45 million, with total second-quarter revenue of $46.5 million. The guidance implies significant scaling from current levels and provides a concrete benchmark for investors. The announcement comes a day after the appointment of Caroline Levy to the board, adding consumer-sector expertise.
Updates
· SEC 6-K — Q2 revenue up 288% YoY, FY26 guidance raised to $220-230M, first positive adjusted FCF month in July.
At the time of this announcement, PRE was trading at $19.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $332.1M. The 52-week trading range was $7.18 to $23.63. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.